 |
Stirling Products Limited (ASX:STI) Gets Approval For TB and HIV Treatment "Immunoxel" In South Africa
MAY 26, 2009 11:53 - Article Views: 2,718
Australian healthcare company Stirling Products Limited (ASX:STI) is pleased to announce another milestone in the expansion of the licensed (pending joint venture approval) botanical products to markets outside of Ukraine. Immunoxel (Dzherelo) has been granted approval in South Africa. This approval will allow immediate sales of the phytoconcentrate as an immune adjuvant for TB and HIV treatment. |
 |
 |
Stirling Products (ASX:STI) Consolidates Licensing Deals
NOV 10, 2008 13:29 - Article Views: 3,330
Stirling Products (ASX:STI) advises shareholders that it has terminated its relationship with West Australian company Cocky Smart Pty Ltd for the exclusive global licensing rights to their novel insecticide compound originally isolated from cockatoo feathers. |
|
|
Stirling Products (ASX:STI) Gets First Approval For Obesity Patent
NOV 7, 2008 12:04 - Article Views: 2,258
Stirling Products (ASX:STI) advises shareholders that it has received notice that its patent application for "Methods of decreasing fat deposits and body weight in mammals and birds" has been granted in New Zealand. Patent applications have been filed in a number of different countries; this represents the first successful approval. |
|
|
Stirling Products Limited (ASX:STI) Launches Animal Product PetQuench In North America
OCT 1, 2008 12:12 - Article Views: 2,141
Stirling Products (ASX:STI) advises shareholders that it launched PetQuench(tm), the first of its companion animal products, at one of Canada's largest pet shows last weekend. PetQuench(tm) was released onto the Canadian market through Stirling Animal Health at the prestigious PIJAC National Industry Trade Show in Ontario, Canada. |
|
|
Stirling Products (ASX:STI) Announces Consolidation Of Stirling North American Operation
SEP 11, 2008 13:19 - Article Views: 2,818
Stirling Products (ASX:STI) advises shareholders that it has commenced a consolidation process that will result in a dedicated subsidiary for its global sales and marketing efforts. Stirling has over the last two years undergone a growth and acquisition phase with the establishment of the Danish joint venture Pulmovet in July 2006 (ASX: July 13, 2006), the acquisition of Progressive BioActives Inc. |
|
|
Stirling Products (ASX:STI) Signs First Product For Companion Animals
AUG 14, 2008 13:35 - Article Views: 2,660
Stirling Products (ASX:STI) advises shareholders that it has now completed the transaction to acquire worldwide licensing rights for the product PetQuench(tm). PetQuench(tm), fortified water for dogs and cats, is already on the market in North America and is expected to be launched in Australia by the end of Q1 2009. |
|
|
Stirling Products (ASX:STI) Gets Australian Patent For Heaves In Horses
JULY 28, 2008 16:57 - Article Views: 2,010
Stirling Products (ASX:STI) wishes to advise shareholders that its patent application for "the treatment of heaves in horses" with R-salbutamol has now been granted in Australia. The company previously announced that the patent had also been approved in South Africa (ASX, October 10, 2006). |
|
|
Stirling Products (ASX:STI) Announce Provale(tm) Effective At Inhibiting Loma Infection In Rainbow Trout
JULY 15, 2008 12:28 - Article Views: 1,521
Stirling Products North America Inc (STI-NA)(ASX:STI) has presented results of a ground-breaking study into the Loma gill disease infection of farmed fish, especially salmon and trout, at the 2008 Annual Meeting of the American Fisheries Society (FHS-AFS). The results presented demonstrate the effectiveness of Stirling's proprietary beta glucan product, ProVale(tm), in inhibiting the impact of Loma salmonae, a costly and untreatable disease in farmed fish, especially Pacific salmon. |
|
|
AUDIO: Stirling Products Limited ASX:STI Excellence In Biotechnology Investment - Dr Calvin London, MD
JUNE 24, 2008 15:03 - Article Views: 1,336
Stirling Products Limited Excellence in Biotechnology Investment - Dr Calvin London, MD, Stirling Products Ltd; Stirling Products Limited (ASX: STI) present the following audio webcast regarding "Excellence in Biotechnology Investment - Dr Calvin London, MD, Stirling Products Ltd". You may also download this audio webcast to your computer or portable audio player.
|
|
|
